title: The FKBP-rapamycin binding domain of human TOR undergoes strong conformational changes in the presence of membrane mimetics with and without the regulator phosphatidic acid.
abstract: The Ser/Thr kinase target of rapamycin (TOR) is a central controller of cellular growth and metabolism. Misregulation of TOR signaling is involved in metabolic and neurological disorders and tumor formation. TOR can be inhibited by association of a complex of rapamycin and FKBP12 to the FKBP12-rapamycin binding (FRB) domain. This domain was further proposed to interact with phosphatidic acid (PA), a lipid second messenger present in cellular membranes. Because mammalian TOR has been localized at various cellular membranes and in the nucleus, the output of TOR signaling may depend on its localization, which is expected to be influenced by the interaction with complex partners and regulators in response to cellular signals. Here, we present a detailed characterization of the interaction of the FRB domain with PA and how it is influenced by the surrounding membrane environment. On the basis of nuclear magnetic resonance- and circular dichroism-monitored binding studies using different neutral and negatively charged lipids as well as different membrane mimetics (micelles, bicelles, and liposomes), the FRB domain may function as a conditional peripheral membrane protein. However, the data for the isolated domain just indicate an increased affinity for negatively charged lipids and membrane patches but no specific preference for PA or PA-enriched regions. The membrane-mimetic environment induces strong conformational changes that largely maintain the α-helical secondary structure content but presumably disperse the helices in the lipidic environment. Consistent with overlapping binding surfaces for different lipids and the FKBP12-rapamycin complex, binding of the inhibitor complex protects the FRB domain from interactions with membrane mimetics at lower lipid concentrations.
authors.affiliation: Biomolecular NMR Spectroscopy, Department of Chemistry, Technische Universität München, Munich, Germany.
authors.forename: Diana C
authors.initials: DC
authors.lastname: Rodriguez Camargo
authors.forename: Nina M
authors.initials: NM
authors.lastname: Link
authors.forename: Sonja A
authors.initials: SA
authors.lastname: Dames
mesh_terms: D002462:Cell Membrane / Q000737:chemistry*; D006801:Humans; D008081:Liposomes / Q000494:pharmacology*; D008823:Micelles; D008958:Models, Molecular; D010712:Phosphatidic Acids / Q000494:pharmacology*; D017433:Protein Structure, Secondary / Q000187:drug effects; D017434:Protein Structure, Tertiary / Q000187:drug effects; D020123:Sirolimus / Q000378:metabolism*; D058570:TOR Serine-Threonine Kinases / Q000737:chemistry* / Q000378:metabolism; D022061:Tacrolimus Binding Protein 1A / Q000378:metabolism*
chemical_list: D008081:Liposomes; D008823:Micelles; D010712:Phosphatidic Acids; D058570:TOR Serine-Threonine Kinases; D022061:Tacrolimus Binding Protein 1A; D020123:Sirolimus